Skip to content
    CVS
    Earnings call· Jun 2026(Q2 FY26)

    CVS HEALTH Q2 FY26 earnings call CVS

    Aug 5, 2026 Source

    Executive summary

    CVS Health Q2 FY26 — Strong Performance Drives Raised Full-Year Outlook

    CVS Health delivered strong Q2 FY26 results, with all segments growing earnings and exceeding expectations, leading to a significant raise in full-year adjusted EPS and cash flow guidance. The company is leveraging its integrated assets, technology, and AI to enhance consumer and provider experiences, particularly in GLP-1 management and claims processing. While facing headwinds in the 340B program and Caremark membership for FY27, management remains confident in its long-term mid-teens adjusted EPS CAGR target, driven by Aetna's margin recovery, specialty pharmacy strength, and retail momentum.

    Highlights

    5

    • Adjusted operating income grew over 35% to approximately $5.2 billion in Q2 FY26.

    • Adjusted EPS increased over 40% to $2.58 in Q2 FY26.

    • Full-year 2026 adjusted EPS guidance raised by $0.60 to a range of $7.90 to $8.10.

    • Full-year 2026 cash flow from operations guidance raised by $2 billion to at least $11.5 billion.

    • Health Care Benefits segment delivered over $2 billion of year-over-year improvement in adjusted operating income.

    Concerns

    5

    • The 340B business experienced pressure in Q2 FY26 and is expected to be a headwind in FY27.

    • Caremark expects membership declines in FY27 due to disciplined client renewals and health plan market exits.

    • The exit from the individual exchange business in FY26 drove a 700,000 member decline year-over-year in Health Care Benefits.

    • Regulatory-related price reductions and generic drug introductions largely offset revenue increases in Pharmacy and Consumer Wellness.

    • The No Surprises Act's independent dispute resolution (IDR) process is being abused by a small group of players, frustrating self-funded employers.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full-year 2026 Adjusted EPS
    $7.90 to $8.10
    high materiality
    High
    Full-year 2026 Cash flow from operations
    at least $11.5 billion
    high materiality
    High
    Full-year 2026 Total revenues
    at least $414 billion
    medium materiality
    High
    Full-year 2026 Health Care Benefits adjusted operating income
    $5.03 billion to $5.37 billion
    high materiality
    High
    Full-year 2026 Health Care Benefits MBR
    89.75% +/- 25 basis points
    high materiality
    High
    Full-year 2026 Pharmacy and Consumer Wellness adjusted operating income
    at least $6.4 billion
    medium materiality
    High
    Full-year 2026 Health Services adjusted operating income
    reiterated
    medium materiality
    High
    Full-year 2026 Enterprise adjusted operating income
    $16.58 billion to $16.92 billion
    high materiality
    High
    Full-year 2027 Adjusted EPS
    at least $8.44
    high materiality
    Medium
    Adjusted EPS CAGR
    mid-teens
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Health Care Benefits
    Revenue increase primarily driven by government business, partially offset by individual exchange exit. Adjusted operating income and MBR improved meaningfully YoY. Core performance exceeded expectations, largely in Medicare due to strong medical cost management and disciplined pricing. Medicaid and commercial businesses performed in line with expectations.
    Medical membership: 26 million members (Q2 end)Medical membership change: -700,000 YoYMedical Benefit Ratio (MBR): 87.4%MBR impact from risk adjustment/PYD: 140 bps ($500 million)
    		Over $37 billionOver 3%—Approximately $2.4 billion
    Health Services
    Revenue increase primarily driven by pharmacy drug mix and brand inflation, partially offset by pharmacy client price improvements. Adjusted operating income increase driven by improved purchasing economics, pharmacy drug mix, and modest improvement in health care delivery, partially offset by pharmacy client price improvements. Experienced pressure in 340B business, offset by broader Caremark outperformance including higher specialty generic penetration rates.
    Health care delivery revenue growth: Nearly 23% YoY
    		Nearly $52 billionOver 11%—Over $1.7 billion
    Pharmacy and Consumer Wellness
    Revenue driven by pharmacy drug mix, increased prescription volume (including Rite Aid transaction), and brand inflation, largely offset by regulatory-related price reductions, generic drug introductions, and pharmacy reimbursement pressure. Adjusted operating income increase driven by core pharmacy strength and Rite Aid contributions, partially offset by business investments and consumer dynamics.
    Same-store total revenues: modestly increasedSame-store pharmacy sales: Approximately 3% growthSame-store prescription volumes: 7% increaseSame-store front store sales: 100 bps increase
    		Nearly $34 billionSlight increase—Nearly $1.5 billion

    Operational metrics

    12
    Shareholder dividend
    $1.7 billion
    YTD Q2 FY26

    Returned to shareholders year-to-date.

    Cash at parent and unrestricted subsidiaries
    $2.7 billion
    Q2 end

    Balance at the end of the quarter.

    Leverage ratio
    3.5x
    Q2 end

    Expected to drive further improvement.

    Aetna adjusted operating income improvement
    Over $2 billion
    YoY

    Year-over-year improvement delivered so far this year.

    CVS Specialty adherence rates
    Above 90%vs. industry standard of 80%
    Ongoing

    Consistently operates above the industry standard of 80%.

    Biosimilar savings (HUMIRA)
    $1.8 billion
    Ongoing

    Generated through Core Davis biosimilar for customers.

    MinuteClinic virtual weight management offering price
    $29reduced from $49
    Ongoing

    Lowest cost option in the industry, connecting eligible patients with a licensed clinician.

    Claims processing time reduction
    Over 20%
    Ongoing

    Expected reduction in processing time, accelerating payment for providers.

    Prior authorization approval rate (real-time)
    83%
    Ongoing

    Percentage of prior authorizations approved in real-time.

    Prior authorization approval rate (within 24 hours)
    Over 95%
    Ongoing

    Percentage of prior authorizations approved within 24 hours.

    OpEx savings from technology/AI
    Over $1 billion
    Last few years

    Generated through focus on technology efficiencies and AI.

    Pharmacist hours redirected
    Million hours
    Last couple of years

    Removed from retail pharmacy business and transferred to conversational AI, allowing pharmacists to deliver better clinical care.

    Industry KPIs

    9
    MetricValueDetails
    Utilization trendsFavorable
    Stars rate environmentLeading
    Medical loss care ratio87.4%%
    Client retention new winsSlightly lower
    Pharmacy scripts specialtyIncreased
    Membership covered lives by line26 millionmembers
    Segment revenue operating incomeNearly $52 billionUSD
    Adjusted EPS EBITDA leverage guidance$2.58USD
    Medical cost trend vs pricing assumptionStrong medical cost management

    Deals & partnerships

    3
    Eli LillyPartnership for cash-pay pricing and same-day pickup for Zepbound and Mounjaro patients directly through CVS Health's app or in stores.

    Builds on existing relationship with Novo Nordisk for Wegovy, expanding convenient access to GLP-1 therapies.

    Novo NordiskExisting relationship to dispense oral and injectable Wegovy.

    Makes CVS Pharmacy a convenient, affordable destination for all FDA-approved GLP-1s.

    Rite AidTransaction completed last year, contributing to prescription volume growth.

    Contributed to the strong performance of the Pharmacy and Consumer Wellness segment.

    Risks & headwinds

    6
    340B program dynamics and pressureQ2 FY26 and FY27

    Experienced pressure in Q2 FY26, expected headwind in FY27.

    Mitigation: Closely monitoring the environment, working with covered entities (CEs) to navigate program dynamics, and focusing on ensuring value and lowest net cost for clients. Also impacted by large specialty drugs becoming generic.

    Caremark membership declinesFY27

    Trending to a retention rate slightly lower than historical performance, more consistent with industry norms.

    Mitigation: Took a disciplined and prudent approach to the selling season to ensure appropriate underwriting and contracts for new business and renewals. Specialty pharmacy business and robust generic portfolio are expected to partially offset these headwinds.

    Regulatory-related price reductions and generic drug introductionsQ2 FY26

    Largely offset revenue increases in Pharmacy and Consumer Wellness.

    Mitigation: Focus on core pharmacy strength and cost management to mitigate impact.

    Pharmacy reimbursement pressureQ2 FY26

    Impacted Pharmacy and Consumer Wellness revenue.

    Mitigation: CVS Cost Manager program launched to drive more sustainable pharmacy reimbursement and align with payers on value.

    Unconstitutional laws in states like Arkansas and TennesseeOngoing

    Will make care more expensive, less accessible, and more complicated for patients.

    Mitigation: Challenging these laws.

    No Surprises Act Independent Dispute Resolution (IDR) process abuseOngoing

    Process is being abused by a small group of players, frustrating self-funded employers.

    Mitigation: Working with administration and state regulators to resolve the issue. Proactively bringing certain providers into the network at reasonable rates to get ahead of disputes.

    What to watch in Q3 FY26

    5

    Caremark membership retention rate

    Next quarter
    Currenttrending to a retention rate that's slightly lower than our historical performance
    TargetStabilization or improvement towards historical levels

    Why it matters

    Indicates the impact of disciplined underwriting and market dynamics on Caremark's client base, affecting future revenue and profitability.

    As we went into 2027, we took a disciplined and prudent approach to the selling season to ensure they have the right underwriting and contracts in place for the new business and renewals that we had. And at this point in the year, we're trending to a retention rate that's slightly lower than our historical performance. more consistent with industry norms.

    Q&A highlights

    5

    How will CVS offset anticipated 340B headwinds and manage growth in HSS, considering formulary conversion and specialty dynamics, to maintain its growth trajectory?

    Brian Newman reiterated confidence in the mid-teens EPS CAGR for 2025-2028, setting a preliminary FY27 adjusted EPS floor of $8.44. Prem Shah detailed 340B pressure and a more disciplined selling season leading to slightly lower retention rates for Caremark in FY27. He highlighted specialty pharmacy strength, generic pipeline, and innovative solutions like Core Davis biosimilar savings as offsets. David Joyner emphasized Aetna's momentum, retail strength, technology/AI investments, and GLP-1 strategy as enterprise-wide offsets.

    “Overall, I would say we definitely wanted to pull forward the headwinds tailwinds early. But again, talking about the fact that we have some pressure in our PBM at the moment, is more than offset by the strength that we have across the enterprise.”

    asked by Michael Cherny · answered by J. Joyner

    3 min read6 chapters

    Detailed Narrative

    01

    GLP-1 Strategy and Market Opportunity

    CVS Health is positioning itself as a leader in supporting patients utilizing GLP-1s for weight loss, focusing on affordability, access, and convenience. Caremark is taking formulary actions to increase availability at lower costs for employers. For consumers seeking access outside traditional benefits, CVS offers a direct-to-consumer platform, including MinuteClinic's virtual weight management for $29 and cash-pay options for GLP-1 therapies as low as $149. New partnerships with Eli Lilly and existing relationships with Novo Nordisk enable convenient access and fulfillment for FDA-approved GLP-1s through the CVS Health app or in stores, leveraging the role of pharmacists and omnichannel capabilities.

    02

    Technology and AI Investment for Enhanced Experience

    The company is making significant investments in technology and AI, viewing it as central to its differentiation and value proposition. This includes the targeted launch of the Health 100 platform and the AI-powered assistant IO, designed to simplify the consumer experience. AI is also being deployed to improve operational efficiency, such as reducing claims processing time by over 20% with an AI-enabled claims assist manager, and streamlining prior authorizations (83% approved in real-time, over 95% within 24 hours). These efforts aim to reduce friction for consumers and providers while maintaining human touch and privacy.

    03

    Aetna's Continued Margin Recovery and Performance

    Aetna has demonstrated strong performance, delivering over $2 billion of year-over-year improvement in adjusted operating income. This progress is attributed to strengthened clinical programs, improved operations, and disciplined cost management and pricing. The Medicare business, in particular, exceeded expectations due to strong medical cost management and disciplined pricing, with less membership contraction than anticipated. The company remains confident in Aetna's continued momentum towards target margins over the next couple of years, applying the same disciplined approach to FY27 bids.

    04

    Caremark's PBM Transition and Specialty Pharmacy Strength

    Caremark is leading the industry's transition towards net cost price models, expecting acceleration due to recent legislation and regulatory developments. While facing pressure in the 340B business and anticipating membership declines in FY27 due to a disciplined selling season, the specialty pharmacy business remains a key strength. It boasts high generic penetration rates, adherence rates above 90%, and has generated significant savings for clients, such as $1.8 billion from biosimilar HUMIRA through Core Davis. The focus remains on managing drug trends and reducing costs for clients.

    05

    Pharmacy and Consumer Wellness Momentum and Strategy

    The Pharmacy and Consumer Wellness segment continues to build momentum, delivering strong results with a 10% increase in adjusted operating income. This is driven by core pharmacy strength, increased prescription volumes (including contributions from the Rite Aid transaction), and 3% same-store pharmacy sales growth. The strategy involves improving service levels (achieving best NPS), empowering pharmacists for clinical services, and utilizing the CVS Cost Manager program to drive more sustainable pharmacy reimbursement and consistent margin profiles. Strong front-store sales growth of 100 basis points also contributed to performance.

    06

    Provider Partnership and Friction Reduction

    CVS Health is actively working to become the partner of choice for providers by addressing key friction points in the healthcare system. This includes reducing prior authorization burdens, streamlining claims, and improving access to real-time patient information. Initiatives like the AI-enabled claims assist manager, which reduces processing time by over 20%, and the Aetna clinical collaboration program, which embeds nurses in hospitals for care transitions, are designed to enhance connectivity, improve coordination, and build trust with providers.

    AI-generated summary of the company’s earnings call. Not investment advice.